Skip to content
Auro Laboratories logo

Auro Laboratories

530233 BSE
Price unavailable

Auro Laboratories (AUROLAB) share price was ₹229.40 at the 28 Oct 2026 close; market capitalisation ₹143 Cr; P/E (TTM) 30.46; sector Healthcare. The share price rose 14.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 216.6% year on year to ₹8.77 Cr and net profit was ₹1.05 Cr, against −₹0.11 Cr a year earlier (compared with Jun 2025). Promoters held 52.40% of Auro Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 44/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹229.40 +28.40 +14.13% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹143 Cr
P/E (TTM)
30.46
EBITDA
₹12.00 Cr
Return on Equity
7.62%
Debt to Equity
1.37
Book Value
₹74.36
EPS (TTM)
₹7.53
52W High
₹317.00
52W Low
₹159.00

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.7035.054,23,891 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,610.8072.381,75,380 Cr9.550.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.80108.091,18,210 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.3026.291,17,835 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.4034.661,11,714 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.2032.711,10,289 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Auro Laboratories (this company)
—30.46143 Cr3.080.00%7.62%9.79%22 Cr5 Cr
Median 8 companies₹1,766.7034.861,18,022 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

44 Weak
Overall score

Data confidence 95/100

Category scores

Quality Average 53
Returns, margins, earnings quality 22% weight
Valuation Poor 22
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Poor 26
Solvency, leverage, coverage 9% weight
Momentum Weak 43
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

5
  • Stock is trading at 3.10 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -10.7% over past five years.
  • Company has a low return on equity of 10.7% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
10
Neutral
6
Bullish
3

Moving Averages

Bearish

Bearish
8
Neutral
0
Bullish
2

Growth Rate

Revenue Growth
62.69% higher than 3Y

change over 1 year

Net Income Growth
94.44% higher than 3Y

change over 1 year

Cash Flow Change
-57.97%

change over 1 year

EBITDA Margin Change
81.27%

change over 1 year Operating margin 37.63% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
10.18
13.41
17.98
12.06
5.72
3.1
3.05
7.4
2.77
8.84
9.39
9.83
8.77
Expenses
9.02
10.38
13.9
9.65
4.39
2.38
2.6
6.59
2.74
6.49
5.33
6.5
5.47
Operating Profit
1.16
3.03
4.08
2.41
1.33
0.72
0.45
0.81
0.03
2.35
4.06
3.33
3.3
OPM %
11.39%
22.6%
22.69%
19.98%
23.25%
23.23%
14.75%
10.95%
1.08%
26.58%
43.24%
33.88%
37.63%
Other Income
0.36
0.32
0.42
0.4
0.2
0.31
0.14
0.13
0.42
0.98
0.18
0.52
0.11
Interest
0.27
0.35
0.44
-0.32
0.25
0.28
0.25
0.3
0.28
0.96
1.52
1.49
1.37
Depreciation
0.27
0.27
0.27
0.28
0.27
0.27
0.27
0.29
0.27
0.65
0.98
0.9
0.91
PBT
0.98
2.73
3.79
2.85
1.01
0.48
0.07
0.35
-0.1
1.72
1.74
1.46
1.13
Tax %
27.55%
27.84%
27.7%
18.6%
24.75%
25%
28.57%
-11.43%
0%
58.14%
-12.07%
32.88%
7.08%
Net Profit
0.71
1.97
2.73
2.32
0.75
0.36
0.05
0.39
-0.11
0.72
1.95
0.97
1.05
EPS (₹)
1.14
3.16
4.38
3.72
1.2
0.58
0.08
0.63
-0.18
1.16
3.13
1.56
1.68
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
32.65
27.91
35.47
40.79
46.82
43.79
54.25
50.87
52.89
53.64
19.12
30.74
36.83
Expenses
29.71
25.11
31.03
34.43
39.83
37.51
43.01
46.24
48.5
42.96
15.99
20.53
23.79
Operating Profit
2.94
2.8
4.44
6.36
6.99
6.28
11.24
4.63
4.39
10.68
3.13
10.21
13.04
OPM %
9%
10.03%
12.52%
15.59%
14.93%
14.34%
20.72%
9.1%
8.3%
19.91%
16.37%
33.21%
35.41%
Other Income
0.24
0.42
0.53
0.51
0.96
0.97
0.76
1.09
0.94
1.5
0.93
1.66
1.79
Interest
1.66
1.66
1.18
1.21
0.87
0.58
0.46
0.83
0.81
0.74
1.08
4.25
5.34
Depreciation
0.72
0.68
0.86
0.93
1.01
1.02
1.04
1.02
1.07
1.09
1.1
2.81
3.44
PBT
0.8
0.88
2.93
4.73
6.07
5.65
10.5
3.87
3.45
10.35
1.88
4.81
6.05
Tax %
0%
0%
72.01%
25.16%
27.51%
27.96%
31.62%
26.61%
28.99%
24.64%
2.13%
26.61%
—
Net Profit
0.8
0.88
0.82
3.53
4.4
4.05
7.18
2.84
2.44
7.79
1.84
3.53
4.69
EPS (₹)
1.28
1.41
1.32
5.66
7.06
6.5
11.52
4.56
3.91
12.5
2.95
5.66
7.53
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6.23
6.23
6.23
6.23
6.23
6.23
6.23
6.23
6.23
6.23
6.23
6.23
Reserves
1.47
2.35
3.18
6.75
11.18
15.27
22.35
25.29
27.97
35.73
36.74
40.12
Borrowings
16.41
12.62
4.95
9.2
8.09
3.16
3.16
13.78
6.41
26.25
45.01
63.31
Other Liabilities
4.67
4.49
12.45
8.23
7.97
7.68
10.15
9.66
15.38
17.52
11.11
11.42
Total Liabilities
28.78
25.69
26.81
30.41
33.47
32.34
41.89
54.96
55.99
85.73
99.09
121
Fixed Assets
9.8
9.13
13
13.02
14.59
14.24
13.56
13.61
12.62
22.15
21.06
75.18
CWIP
0.82
3.33
0.23
1.07
0.12
0.12
0.13
3.68
7.67
32.68
56.48
14.48
Investments
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.01
Other Assets
18.11
13.18
13.53
16.27
18.71
17.93
28.15
37.62
35.65
30.85
21.5
31.41
Total Assets
28.78
25.69
26.81
30.41
33.47
32.34
41.89
54.96
55.99
85.73
99.09
121
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-0.78
7.88
6.49
6.05
6.87
9.3
12.82
-6.59
3.28
18.81
5.02
2.11
Investing
-0.73
-2.44
-2.2
-3.04
-3.19
-2.21
-3.51
-5.34
-5.08
-38.67
-23.7
-14.78
Financing
0.53
-5.34
-3.81
-1.77
-1.83
-5.52
-0.46
9.79
-8.18
19.09
17.69
14.04
Net Cash Flow
-0.98
0.09
0.47
1.24
1.86
1.58
8.85
-2.14
-9.98
-0.77
-0.99
1.37
Free Cash Flow
-1.55
5.36
4.86
4.25
5.25
8.63
12.44
-11.2
-0.79
18.81
-18.78
-55.03
CFO/OP
-27
281
146
95
98
148
114
-142
75
176
184
21
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
94.8
66.04
79.13
74.9
66.26
48.18
49.12
97.65
85.57
91.11
179
109
Inventory Days
89.37
86.72
21.65
22
42.98
60.54
32.6
47.32
120
113
145
816
Days Payable
56.12
72.03
80.26
78.26
66.19
70.67
73.51
54.12
117
85.34
246
282
Cash Conversion Cycle
128
80.73
20.52
18.64
43.05
38.04
8.2
90.86
88.44
119
78.59
642
Working Capital Days
39.13
26.68
67.2
64.7
63.46
51.09
29.4
36.59
104
35.86
-26.73
6.41
ROCE %
10.74%
11.21%
23.06%
32.51%
29.11%
24.84%
38.87%
12.2%
9.92%
20.38%
3.79%
9.52%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Auro Laboratories insights

66 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs0.01%Promot.52.40%Others10.85%Public36.74%As ofSep 2026

Documents

Frequently Asked Questions about Auro Laboratories

What does Auro Laboratories Ltd do?
Incorporated in 1989, Auro Laboratories Ltd is in the business of Bulk Drugs[1]
Where is Auro Laboratories Ltd (AUROLAB) listed?
Auro Laboratories Ltd trades under code 530233 on the BSE.
Which sector does Auro Laboratories Ltd belong to?
Auro Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Auro Laboratories Ltd?
Auro Laboratories Ltd has a market capitalisation of ₹143.01 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Auro Laboratories Ltd?
Auro Laboratories Ltd trades at a PE ratio of 30.46 as of 28 Oct 2026, on earnings per share of ₹7.53, against a book value of ₹74.36 per share.
What is the 52-week high and low of Auro Laboratories Ltd?
Over the last 52 weeks Auro Laboratories Ltd has traded between ₹159 and ₹317 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Auro Laboratories Ltd?
Auro Laboratories Ltd reported a return on equity of 7.62%. Its debt-to-equity ratio is 1.37.

Company Information

Incorporated in 1989, Auro Laboratories Ltd is in the business of Bulk Drugs[1]

Website aurolabs.com
Face Value ₹ 10
Shares Outstanding 62,33,880

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530233.md for Auro Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month